
Glenmark Pharma shares surge after its U.S arm, AbbVie ink pact for investigational cancer drug
The Hindu
Glenmark Pharmaceuticals' share prices surge 10% on exclusive licensing agreement with AbbVie for ISB 2001 trispecific antibody.
More Related News













